TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05025605: Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Sponsor: BioXcel Therapeutics Inc · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT05025605 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05025605 Rescue Dossier →